Correspondence:
[*]
Correspondence to: Julien Dumurgier, Cognitive Neurology Center, Lariboisiere Hospital, 200 rue du Faubourg Saint Denis, 75010 Paris, France. Tel.: +33 140054313; Fax: +33 140054339; Email: [email protected].
Abstract: Background:CSF Alzheimer’s disease (AD) biomarkers allow classifying individuals based on their levels of amyloid and neurodegeneration pathologies. Objective:To investigate the distribution of AD biomarker profiles from patients suffering from cognitive disorders. Methods:We analyzed 3001 patients with cognitive disorders and referred by 18 French memory clinics located in and around Paris. Patients were classified as normal, amyloidosis (A+/N–), amyloidosis and neurodegeneration (A+/N+) or suspected non-AD pathophysiology (SNAP), according to their CSF levels of biomarkers. Analysis were performed for the overall population and stratified by gender, age quintiles, and Mini-Mental State Examination (MMSE) score quintiles. Results were compared to previous findings in cohorts of healthy elderly adults. Results:37% of the sample were classified as A+/N+, 22% were classified A+/N–, and 15% as SNAP. The A+/N+ profile was associated with female gender, advanced age, and lower MMSE score, while the A+/N–profile was observed more frequently in men and the distribution was stable across age and MMSE. The SNAP profile showed no association with gender or age, was less frequent in patients with lower MMSE, and had a lower repartition than the one previously reported in asymptomatic populations. Conclusions:While A+/N+ patients had the clinical characteristics typically observed in AD, A+/N–patients had a different epidemiological pattern (higher frequency in men, no association with advanced age or lower MMSE). The SNAP profile was less frequent than previously reported in the general elderly population, suggesting that this profile is not a frequent cause of memory impairment in this population.
